retatrutide, the biggest difference is that tirzepatide is already FDA-approved while retatrutide is still in clinical trials , though theres a lot of buzz about its potential benefits
Overall, the role of the gut-liver axis in treating metabolic dysfunction-associated fatty liver disease by GLP-1RAs is essential
In the SURMOUNT 1 Trial (pooling doses), total lean mass was reduced by 8.5 absolute percentage points [15]
In the Phase 2 trial, retatrutide was administered as a once-weekly subcutaneous injection an approach consistent with other incretin-based therapies in this class
The diet is science-adjacent. It borrows from strategies supported by research, but the full program itself has not been studiedand its restrictive structure may be difficult to sustain
Sources such as Cleveland Clinic suggest that GLP-1 drugs help people lose weight, mainly by suppressing appetite and inducing full feelings